MeSH D006966 - hyperprolactinemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Cabergoline | Cabergoline | 2007-03-07 | |||
| Padagis | Bromocriptine | Bromocriptine | 2008-10-01 | |||
| Ingenus | Cabergoline | Cabergoline | 2018-08-01 | |||
| Mylan | Bromocriptine | Bromocriptine | 2005-04-04 | |||
| Cabergoline | Cabergoline | 2013-12-02 | ||||
| Sandoz | Bromocriptine | Bromocriptine | 1998-01-13 | |||
| Pfizer | Cabergoline | Dostinex | 1996-12-23 | |||
| Zydus Therapeutics | Bromocriptine | Bromocriptine | 2008-07-30 | |||
| Apotex | Cabergoline | Cabergoline | 2013-03-08 | |||
| Impax Laboratories | Cabergoline | Cabergoline | 2007-07-03 | |||
| Strides Pharma Global | Cabergoline | Cabergoline | 2005-12-29 |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
100%1/1
Phase 2
0%0/4
Phase 3
50%3/6
Approved: 2Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use